NCT07061925View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

April 23, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Bronchitis
Interventions
DRUG

ALC-2203-1

This group receives ALC-2203-1 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.

DRUG

ALC-2203-2

This group receives ALC-2203-2 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.

DRUG

ALC-2203-AC

This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and ALC-2203-AC, administered three times daily for 7 days.

DRUG

Placabo

This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and a placebo matching ALC-2203-AC, administered three times daily for 7 days.

Trial Locations (1)

05030

RECRUITING

Konkuk University Medical Center, Seoul

All Listed Sponsors
lead

Korea Arlico Pharm. Co., Ltd

INDUSTRY